Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Revolution Medicines, Inc.NASDAQ: RVMD
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow shrinks to $0
Q2 FY2026 stock-based compensation was $0, compared with $28.83M a year earlier. Trailing-twelve-month stock-based compensation was $151.77M. Over 3 fiscal years it compounded at +56.0% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $37.94M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 118.39M USD
- Year-over-year change
- +49.5%
- 4-year CAGR
- +54.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 118.39M | +49.5% |
| FY2024 | 2024-12-31 | 79.2M | +28.2% |
| FY2023 | 2023-12-31 | 61.77M | +98.0% |
| FY2022 | 2022-12-31 | 31.2M | +50.5% |
| FY2021 | 2021-12-31 | 20.72M | — |
Stock-Based Compensation vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's LTM Jun 2026 stock-based compensation of $151.77M is the largest of the 11 companies compared; the peer median is $38.24M.
- Its year-over-year change of +56.3% is the 3rd highest of 11, against a peer median of +28.4%.
- Over three fiscal years its annual growth of +56.0% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $151.77M | +56.3% | +56.0% | — | |
| LTM Sep 2026 | $58.58M | +109.9% | +22.9% | — | |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Jun 2026 | $48.31M | -34.7% | +3.6% | 466.8% | |
| LTM Sep 2026 | $41.68M | +54.1% | +120.1% | — | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Sep 2026 | $35.82M | +41.1% | +7.4% | — | |
| LTM Mar 2026 | $25.38M | +66.4% | — | — | |
| LTM Mar 2026 | $19.52M | +5.2% | +17.4% | 45.4% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $6.38M | -39.9% | -18.4% | — | |
| Peer median (excluding RVMD) | $38.24M | +28.4% | +15.9% | 22.4% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (187.09M) | (248.71M) | (436.37M) | (600.09M) | (1.13B) |
| Depreciation & Amortization | 7.33M | 9.66M | 9.31M | 11.82M | 16.56M |
| Deferred Income Tax | 0 | (419K) | (3.91M) | (762K) | 0 |
| Stock-Based Compensation | 20.72M | 31.2M | 61.77M | 79.2M | 118.39M |
| Change in Working Capital | 8.72M | (13.49M) | 40.66M | 1.17M | 86.82M |
| Accounts Receivables | 464K | 1.26M | 3.42M | 1.25M | 0 |
| Inventory | 7.68M | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.24M | 7.29M | 32.47M | (6.47M) | 9.54M |
| Other Working Capital | (1.66M) | (22.03M) | 4.77M | 6.38M | 77.29M |
| Other Non-Cash Items | 3.13M | (2.64M) | (22.04M) | (48.77M) | 11.79M |
| Operating Cash Flow | (147.18M) | (224.4M) | (350.57M) | (557.44M) | (897.74M) |
| Capital Expenditures | (6.53M) | (10.82M) | (7.73M) | (10.31M) | (15.99M) |
| Acquisitions (Net) | 135.59M | 13.3M | 0 | 0 | 0 |
| Purchases of Investments | (671.34M) | (612.77M) | (1.06B) | (2.14B) | (1.79B) |
| Sales of Investments | 535.75M | 599.47M | 724.05M | 1.59B | 1.93B |
| Other Investing Activities | (135.59M) | (13.3M) | 0 | 0 | 0 |
| Investing Cash Flow | (142.12M) | (24.12M) | (342.6M) | (554.39M) | 118.06M |
| Debt Repayment | 0 | 0 | 0 | 0 | 244.22M |
| Common Stock Issued | 291.24M | 298.05M | 392.39M | 959.13M | 377.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.94M | 3.39M | 836.81M | 284K | 220K |
| Financing Cash Flow | 294.18M | 301.43M | 1.23B | 959.41M | 621.52M |
| Effect of Forex Changes | 0 | 0 | (1.29M) | (667K) | 0 |
| Net Change in Cash | 4.88M | 52.92M | 534.74M | (153.08M) | (158.16M) |
| Free Cash Flow | (153.71M) | (235.22M) | (358.3M) | (567.74M) | (913.73M) |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.